| Research Topics: |
| INDEX |
| AI-chat 1 |
| PRIME 37 |
| aging 12 |
| body 2 |
| brain 17 |
| brainwave 3 |
| cancer 7 |
| climate 3 |
| cognition 10 |
| covid-19 6 |
| crime 3 |
| culture 3 |
| diabetes 6 |
| diagnostics 2 |
| disease 3 |
| drugs 1 |
| energy 1 |
| exercise 3 |
| eyes 1 |
| genetics 12 |
| gut 3 |
| heart 15 |
| immune 8 |
| kidneys 5 |
| language 2 |
| metabolism 2 |
| microbiome 2 |
| nutrition 11 |
| obesity 2 |
| physical 2 |
| politics 2 |
| pollution 2 |
| population 2 |
| practice 2 |
| privacy 2 |
| psychology 14 |
| quantum 1 |
| reproduction 2 |
| rights 1 |
| sleep 2 |
| space 1 |
| tech 2 |
| unk |
| vaccine 2 |
| virus 2 |
| war-confl |
| war-cyber 1 |
|
Scanned: 3012 Evaluated: 322 Selected: 92 |
| IMMUNE VACCINE | ||||||||
Mim32-002 | First-in-Human, Randomized, Placebo-Controlled, Double-Blind Phase 1 Study to Assess in Healthy Adults the Safety and Immunogenicity of Intramuscularly Administered AAVLP-HPV Vaccine | |||||||
| Quote: | Repeat vaccination with AAVLP-HPV elicited L2-specific neutralizing antibodies of modest titer in serum. Antibodies cross-reactive with L2 of diverse HPV types were detected, but responses were weak in most vaccinees. We conclude that while AAVLP-HPV vaccination is well tolerated, an adjuvant is likely needed to consistently elicit durable and broadly neutralizing responses. | |||||||
| Abstract: | https://www.medrxiv.org/content/10.64898/2026.08.07.26359762v1 | |||||||
| Full Text: | https://www.medrxiv.org/content/10.64898/2026.08.07.26359762v1.full-text | |||||||
| Search Similar: | Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho | |||||||
| Search Authors: | Jeanette Prangsgaard Emma Huus Jade Alvarez Richard BS Roden Mrtina Mueller Qingxin Chen Preben Bruun Nyzell John Dirk Vestergaard Nieland, | |||||||
| PRIME BRAIN GENETICS VACCINE VIRUS | ||||||||
Mne32-006 | Aggregation and analysis of 25 years of prion disease natural history extracted from published literature | |||||||
| Quote: | Background and Objectives. Prion disease is an untreatable, typically rapidly progressive dementia. New drug candidates designed to lower prion protein are now entering clinical trials. To support future pivotal trials, we sought to assemble and analyze a public dataset of natural history data characterizing the symptomatic course of prion disease in order to provide a quantitative basis for modelling and rational trial design. | |||||||
| Abstract: | https://www.medrxiv.org/content/10.64898/2026.08.07.26359973v1 | |||||||
| Full Text: | https://www.medrxiv.org/content/10.64898/2026.08.07.26359973v1.full-text | |||||||
| Search Similar: | Brave Mojeek Startpage Dogpile Bing Googl Lycos Utub Yaho | |||||||
| Search Authors: | Leo MH Xu Daniel A Sprague Sonia M Vallabh Eric Vallabh Minikel, | |||||||
|
Javilk's Research Links Newsletter for Week 32 Updated 08/15/2026-01:24:35 AM What interests you? What have you found? Tell me! Drop me a note to subscribe or submit something. |